Literature DB >> 23184900

The effects of vitamin D repletion on endothelial function and inflammation in patients with coronary artery disease.

Seth I Sokol1, Vankeepuram Srinivas, Jill P Crandall, Mimi Kim, George Tellides, Amir H Lebastchi, Amir Lebastchi, Yiting Yu, Alok K Gupta, Michael H Alderman.   

Abstract

Adequate vitamin D levels may promote cardiovascular health by improving endothelial function and down-regulating inflammation. The objective of this pilot trial was to investigate the effects of vitamin D repletion on endothelial function and inflammation in patients with coronary artery disease (CAD). Using a double-blind placebo wait-list control design, 90 subjects with CAD and vitamin D deficiency (< 20 ng/ml) were randomized 1:1 to 50,000 IU of oral ergocalciferol or placebo weekly for 12 weeks. Endothelial function (reactive hyperemia peripheral arterial tonometry, RH-PAT), circulating adhesion molecules, and pro-inflammatory cytokines were measured at baseline and 12 weeks. The median increase in serum 25-vitamin D from baseline was 26 ± 17 ng/ml in the active group and 4 ± 8 ng/ml in the placebo group (between-group difference = 22 ng/ml, p < 0.001). The median within-subject change in RH-PAT score was 0.13 ± 0.73 with active treatment and -0.04 ± 0.63 with placebo (between-group difference = 0.17, p = 0.44). Within-group and between-group differences in intercellular adhesion molecule levels were greater with placebo (between-group difference = 6 ng/ml, p = 0.048). Vascular cell adhesion molecule levels decreased in both groups by a similar magnitude (median difference between groups = 8.5 ng/ml, p = 0.79). There was no difference between groups in magnitude of reduction in interleukin (IL)-12 (-8.6 ng/ml, p = 0.72) and interferon-gamma (0.52 ng/ml, p = 0.88). No significant differences in blood pressure, e-selectin, high-sensitivity c-reactive protein, IL-6 or the chemokine CXCL-10 were found with treatment. In conclusion, repleting vitamin D levels in subjects with CAD failed to demonstrate any benefits on surrogate markers of cardiovascular health. These results question the role of vitamin D supplementation in modifying cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23184900     DOI: 10.1177/1358863X12466709

Source DB:  PubMed          Journal:  Vasc Med        ISSN: 1358-863X            Impact factor:   3.239


  42 in total

1.  Randomized controlled trial of calcitriol in severe sepsis.

Authors:  David E Leaf; Anas Raed; Michael W Donnino; Adit A Ginde; Sushrut S Waikar
Journal:  Am J Respir Crit Care Med       Date:  2014-09-01       Impact factor: 21.405

2.  Evidence-based nutritional and pharmacological interventions targeting chronic low-grade inflammation in middle-age and older adults: A systematic review and meta-analysis.

Authors:  C Custodero; R T Mankowski; S A Lee; Z Chen; S Wu; T M Manini; J Hincapie Echeverri; C Sabbà; D P Beavers; J A Cauley; M A Espeland; R A Fielding; S B Kritchevsky; C K Liu; M M McDermott; M E Miller; R P Tracy; A B Newman; W T Ambrosius; M Pahor; S D Anton
Journal:  Ageing Res Rev       Date:  2018-05-25       Impact factor: 10.895

3.  Vitamin D and Ischaemic Heart Disease: A Casual or A Causal Association? : Commentary on: "Raslan E et al. Association of Vitamin D Deficiency with Chronic Stable Angina: A Case-Control Study".

Authors:  Damiano Rizzoni; Marco Rizzoni; Matteo Nardin
Journal:  High Blood Press Cardiovasc Prev       Date:  2019-01-23

4.  The effects of vitamin D supplementation on proatherogenic inflammatory markers and carotid intima media thickness in subjects with metabolic syndrome: a randomized double-blind placebo-controlled clinical trial.

Authors:  Shabnam Salekzamani; Abolhassan Shakeri Bavil; Hossein Mehralizadeh; Mohammad Asghari Jafarabadi; Aymaral Ghezel; Bahram Pourghassem Gargari
Journal:  Endocrine       Date:  2017-05-16       Impact factor: 3.633

5.  Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease.

Authors:  Tina K Thethi; Muhammad A Bajwa; Husam Ghanim; Chanhee Jo; Monica Weir; Allison B Goldfine; Guillermo Umpierrez; Cyrus Desouza; Paresh Dandona; Ying Fang-Hollingsworth; Vasudevan Raghavan; Vivian A Fonseca
Journal:  J Diabetes Complications       Date:  2015-01-13       Impact factor: 2.852

6.  Race/ethnicity, serum 25-hydroxyvitamin D, and heart disease.

Authors:  Keith C Norris; Sandra F Williams
Journal:  JAMA       Date:  2013-07-10       Impact factor: 56.272

7.  Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis.

Authors:  Egil Røsjø; Linn H Steffensen; Lone Jørgensen; Jonas C Lindstrøm; Jūratė Šaltytė Benth; Annika E Michelsen; Pål Aukrust; Thor Ueland; Margitta T Kampman; Øivind Torkildsen; Trygve Holmøy
Journal:  J Neurol       Date:  2015-10-01       Impact factor: 4.849

Review 8.  Effectiveness of Vitamin D Supplementation for Cardiovascular Health Outcomes.

Authors:  Panagiota Veloudi; Graeme Jones; James E Sharman
Journal:  Pulse (Basel)       Date:  2016-12-09

9.  Vitamin D receptor protein is associated with interleukin-6 in human skeletal muscle.

Authors:  Rachele M Pojednic; Lisa Ceglia; Alice H Lichtenstein; Bess Dawson-Hughes; Roger A Fielding
Journal:  Endocrine       Date:  2014-12-16       Impact factor: 3.633

10.  1,25(OH)2D3 inhibits oxidative stress and monocyte adhesion by mediating the upregulation of GCLC and GSH in endothelial cells treated with acetoacetate (ketosis).

Authors:  Preeti Kanikarla-Marie; Sushil K Jain
Journal:  J Steroid Biochem Mol Biol       Date:  2016-03-03       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.